Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at restoring healthy gut function.

The molecule has shown promise in treating celiac disease, with potential applications for other gastrointestinal disorders such as Crohn's disease and ulcerative colitis. Immunic Inc. plans to conduct a Phase 2 clinical trial for IMU-856 in celiac disease patients and explore other potential applications, saying that the phase 1b results "clearly go beyond" initial expectations.

Contact Details

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com